
Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.

Dana Holger, PharmD, MPH, AAHIVP, practices as an assistant professor in the Department of Pharmacy Practice at Nova Southeastern University in Fort Lauderdale, Florida. (ORCID 0000-0001-7171-7015)

Emerging preclinical, compassionate-use, and randomized trial data suggest phage-antibiotic combinations may benefit select patients with multidrug-resistant infections, yet critical gaps in standardization and evidence remain.

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.